<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059770</url>
  </required_header>
  <id_info>
    <org_study_id>Three L-AmB Regimens in Histo</org_study_id>
    <nct_id>NCT04059770</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients</brief_title>
  <official_title>Open Label Phase-II Randomized Trial of Three Liposomal Amphotericin B Regimens as Induction Therapy for Disseminated Histoplasmosis in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alessandro Pasqualotto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nossa Senhora da Conceicao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Health Science of Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disseminated histoplasmosis (DH) is one of the major AIDS-defining infections responsible for&#xD;
      high mortality rates in HIV-infected patients. Liposomal amphotericin B (L-AmB) is considered&#xD;
      the therapy of choice for AIDS-associated histoplasmosis.However, many patients in Latin&#xD;
      America are still treated with high doses of deoxycholate amphotericin B (d-AmB) for long&#xD;
      periods. These regimens are associated with toxicity and thus reduced efficacy. Therefore, a&#xD;
      better treatment strategy is necessary to improve the activity of this amphotericin B&#xD;
      treatment. Treatment with a high dose of L-AmB for short periods (rather than standard doses&#xD;
      for longer periods) is a promising approach considering that the antifungal effect of&#xD;
      amphotericin B depends on peak concentrations. This randomized open-label Phase II study aims&#xD;
      to determinate and to compare the activity and safety of three L-AmB regimens, as induction&#xD;
      therapy for DH in AIDS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized non-comparative multicenter open label trial of induction&#xD;
      therapy with LAmB for DH in AIDS patients, followed by oral therapy with itraconazole.&#xD;
&#xD;
      The sample size planned is 99 patients of both sexes, older than 18 years (33 patients per&#xD;
      study arm), infected with HIV and with confirmed diagnosis for DH. This sample size considers&#xD;
      10% of dropout.&#xD;
&#xD;
      The study will be conducted in accordance with the Helsinki Declaration, as well as the&#xD;
      Standards national and international Guidelines for Good Clinical Practices.&#xD;
&#xD;
      Eight research centres in Brazil will competitively recruit patients: Santa Casa de&#xD;
      Misericórdia de Porto Alegre (Porto Alegre; Dr Alessandro C. Pasqualotto), Hospital de&#xD;
      Clínicas de Porto Alegre (Porto Alegre; Dr Diego R. Falci), Hospital Nossa Senhora da&#xD;
      Conceição (Porto Alegre; Dr Marineide Melo), Hospital de Doenças Tropicais (Goiânia; Dr&#xD;
      Cassia S. de Miranda Godoy), Hospital São José de Doenças Infecciosas (Fortaleza; Dr&#xD;
      Terezinha M. J. Silva Leitão), and Hospital Giselda Trigueiro (Natal, Dr Monica B. Bay),&#xD;
      Hospital Universitário Osvaldo Cruz (Recife, Dr. Filipe Prohaska Batista) e Instituto de&#xD;
      Infectologia Emília Ribas (São Paulo, Dr. José Ernesto Vidal Bermudez).&#xD;
&#xD;
      AIDS patients with DH will be randomized to one of three study arms:&#xD;
&#xD;
      (i) single IV dose of 10 mg/kg of L-AmB; (ii) single IV dose of 10 mg/kg of L-AmB on day 1,&#xD;
      followed by 5 mg/kg of L-AmB on day 3; (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.&#xD;
&#xD;
      Induction therapy will be followed in all patients by oral therapy with itraconazole capsules&#xD;
      at 400 mg/daily for a year, azole drug which is already therapy of choice for consolidation&#xD;
      of histoplasmosis, according to national and international Guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>day 14</time_frame>
    <description>Maximum daily temperature lower than 37.8 °C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight stability</measure>
    <time_frame>day 14</time_frame>
    <description>This parameter will be measurement by a questionnaire, based on information about the patient weight in kilograms (Kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>day 14</time_frame>
    <description>Analysis if any patient presented hypotension (systolic blood pressure ˂ 90 mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood oxygen level</measure>
    <time_frame>day 14</time_frame>
    <description>Normal arterial oxygen is approximately 75 to 100 millimeters of mercury (mm Hg). Values under 60 mm Hg usually indicate the need for supplemental oxygen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>day 14</time_frame>
    <description>Mortality rates attributed to the cause of death that is not directly and only related to histoplasmosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to histoplasmosis</measure>
    <time_frame>day 14</time_frame>
    <description>Mortality rates attributed by the study investigator that are directly related to histoplasmosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function abnormalities</measure>
    <time_frame>day 14</time_frame>
    <description>Microalbuminuria &gt; 30 mg/24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function abnormalities</measure>
    <time_frame>day 14</time_frame>
    <description>Liver function abnormalities were serum levels of alanine and aspartate aminotransferase &gt; 2.5 times normal or bilirubin levels &gt; 2 times normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histoplasma urinary antigen concentrations</measure>
    <time_frame>day 7, 14</time_frame>
    <description>Decrease of at least 50% in Histoplasma urinary antigen concentrations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Histoplasmosis</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>single dose of L-AmB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single IV dose of 10 mg/kg of L-AmB on day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of L-AmB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 weeks of L-AmB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV dose of 3 mg/kg of L-AmB for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of L-AmB</intervention_name>
    <description>(i) single IV dose of 10 mg/kg of L-AmB on day 1;</description>
    <arm_group_label>single dose of L-AmB</arm_group_label>
    <other_name>Intervention 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 doses of L-AmB</intervention_name>
    <description>(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;</description>
    <arm_group_label>2 doses of L-AmB</arm_group_label>
    <other_name>Intervention 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 weeks of L-AmB</intervention_name>
    <description>(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.</description>
    <arm_group_label>2 weeks of L-AmB</arm_group_label>
    <other_name>Intervention 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt; 18 years) HIV-infected hospitalized patients diagnosed with HD by the means&#xD;
             of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii)&#xD;
             confirmation by classical mycological methods (microscopy, culture or histopathology);&#xD;
             or (iii) Histoplasma positive qualitative polymerase chain reaction (PCR) in&#xD;
             bronchoalveolar lavage samples, bone marrow aspirates or tissue samples.&#xD;
&#xD;
          -  Patients will be included despite of the use of antiretroviral therapy (ART).&#xD;
&#xD;
          -  Understanding and signed the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous diagnosis of histoplasmosis.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients with renal insufficiency (serum creatinine and urea &gt; 1.5x the upper limit of&#xD;
             normal).&#xD;
&#xD;
          -  Abnormal aminotransferases (up to &gt; 3x the upper limit of normal) and patients with a&#xD;
             severe prior reaction to polyene antifungal.&#xD;
&#xD;
          -  Patients who have received more than one dose of a polyene antifungal in the last 48&#xD;
             hours.&#xD;
&#xD;
          -  Patients who refuse to participate in the study.&#xD;
&#xD;
          -  Patients diagnosed with histoplasmosis that affect the central nervous system.&#xD;
&#xD;
          -  Patients who, at the trial of the attending physician, are expected to die within 48&#xD;
             hours.&#xD;
&#xD;
          -  Patients diagnosed with tuberculosis.&#xD;
&#xD;
          -  Patients with any disease or condition that, in the opinion of the investigator, may&#xD;
             interfere with the assessments or participation in the study.&#xD;
&#xD;
          -  Patients receiving drugs that cause significant (relative or absolute) drug&#xD;
             interaction with Itraconazole.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiane Dalla Lana, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro C. Pasqualotto, MD PhD</last_name>
    <phone>55 51 999951614</phone>
    <email>acpasqualotto@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cássia Caurio</last_name>
    <phone>55 51 995888081</phone>
    <email>cassiacaurio@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Pasqualotto, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Health Science of Porto Alegre</investigator_affiliation>
    <investigator_full_name>Alessandro Pasqualotto</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <keyword>AIDS</keyword>
  <keyword>Liposomal amphotericin B</keyword>
  <keyword>High dose therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

